Clin Exp Otorhinolaryngol.  2020 Feb;13(1):36-40. 10.21053/ceo.2019.00283.

A Prognostic Marker in Idiopathic Sudden Sensorineural Hearing Loss: Serum Calprotectin

• Kuzucu
• Çandar T
• Baklacı D
• Güler
• Kum RO
• Arslan H
• Özcan M

• KMID: 2501295
• DOI: http://doi.org/10.21053/ceo.2019.00283

Abstract

Objectives
. Calprotectin, a protein released by neutrophils, has been used in many studies as a biomarker showing the presence of inflammation. In this study, it was aimed to investigate the relationship between serum calprotectin level and response to the treatment of idiopathic sudden sensorineural hearing loss (ISSHL).
Methods
. The present study is a prospective, cross-sectional historical cohort study. The study group consisted of 44 patients with ISSHL, and the control group consisted of 41 healthy volunteers without ear pathology. At the same time, patients in the study group were divided into three groups according to the response to ISSHL treatment (recovered, partially recovered, unrecovered). The relationship between the groups was statistically evaluated in terms of serum calprotectin levels.
Results
. The mean serum calprotectin value was 75.67±19.48 ng/mL in the study group and 50.24±29.14 ng/mL in the control group (P=0.001). Serum calprotectin value according to the severity of hearing loss in the mild, moderate and severe was 66.20±8.82, 70.35±16.77, and 91.23±19.73 ng/mL, respectively. Serum calprotectin value in the severe group was significantly higher compared to the moderate and mild groups (P=0.004, P=0.001, respectively). Serum calprotectin value according to the treatment response in the recovered, partially recovered and unrecovered groups was 63.36±11.54, 80.17±12.06, and 85.33±22.33 ng/mL, respectively. Serum calprotectin value in the recovered group was significantly lower compared to the partially recovered and unrecovered groups (P=0.002, P=0.001, respectively).
Conclusion
. Serum calprotectin value informs the clinician about both the severity of hearing loss and the response to treatment. Hence, serum calprotectin can be used as an important biomarker in ISSHL patients for the determination of the prognosis of disease.

Keyword

Calprotectin; Idiopathic; Sensorineural Hearing Loss

Reference

1. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012; Mar. 146(3 Suppl):S1–35.

2. Sano H, Okamoto M, Ohhashi K, Iwasaki S, Ogawa K. Quality of life reported by patients with idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2013; Jan. 34(1):36–40.

3. Kim JY, Lee JW, Kim M, Kim MJ, Kim DK. Association of idiopathic sudden sensorineural hearing loss with affective disorders. JAMA Otolaryngol Head Neck Surg. 2018; Jul. 144(7):614–21.

4. Topuz MF, Binnetoglu A, Yumusakhuylu AC, Sari M, Baglam T, Gerin F. Circulating calprotectin as a biomarker of laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2017; Jun. 274(6):2499–504.

5. Striz I, Trebichavsky I. Calprotectin: a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004; 53(3):245–53.

6. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007; Sep. 13(9):1042–9.

7. Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010; Jun. 16(6):713–7.

8. Van Crombruggen K, Vogl T, Perez-Novo C, Holtappels G, Bachert C. Differential release and deposition of S100A8/A9 proteins in inflamed upper airway tissue. Eur Respir J. 2016; Jan. 47(1):264–74.

9. Gurgel RK, Jackler RK, Dobie RA, Popelka GR. A new standardized format for reporting hearing outcome in clinical trials. Otolaryngol Head Neck Surg. 2012; Nov. 147(5):803–7.

10. Kum RO, Ozcan M, Baklaci D, Yurtsever Kum N, Yilmaz YF, Unal A, et al. Investigation of neutrophil-to-lymphocyte ratio and mean platelet volume in sudden hearing loss. Braz J Otorhinolaryngol. 2015; Nov-Dec. 81(6):636–41.

11. Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, et al. Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecol Oncol. 2009; Sep. 114(3):491–5.

12. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003; Jun. 26(6):753–60.

13. Masuda M, Kanzaki S, Minami S, Kikuchi J, Kanzaki J, Sato H, et al. Correlations of inflammatory biomarkers with the onset and prognosis of idiopathic sudden sensorineural hearing loss. Otol Neurotol. 2012; Sep. 33(7):1142–50.

14. Ozler GS. Increased neutrophil-lymphocyte ratio in patients with idiopathic sudden sensorineural hearing loss. J Craniofac Surg. 2014; May. 25(3):e260–3.

15. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss. II. A meta-analysis. Arch Otolaryngol Head Neck Surg. 2007; Jun. 133(6):582–6.

16. Lee AT, Tong MC, Yuen KC, Tang PS, Vanhasselt CA. Hearing impairment and depressive symptoms in an older chinese population. J Otolaryngol Head Neck Surg. 2010; Oct. 39(5):498–503.